

I. Biographical and Bibliographic Information

A. Identifying Data

1. Name: Ann Weinacker, M.D.

B. Complete Academic History

1. Colleges and Universities Attended

- | | |
|-------------|--|
| 1973 - 1976 | Registered Nurse, Diploma
Mastin School of Nursing, Mobile, AL |
| 1973 - 1982 | No Degree Conferred
University of South Alabama, Mobile, AL |
| 1978 - 1980 | Certified Registered Nurse Anesthetist, Diploma
University of South Alabama School of Anesthesia for Nurses
Mobile, AL |
| 1982 - 1986 | M.D. University of South Alabama College of Medicine, Mobile, AL |

2. Scholarships and Honors (In training)

- | | |
|------|--|
| 1986 | Award for Service to Medical School |
| 1987 | Best Intern Award, University of South Alabama |
| 1989 | Victor Benator Award for Best Teaching Resident, University of South Alabama |

3. Post-doctoral and Residency Training

- | | |
|-------------|---|
| 1986 - 1989 | Internal Medicine Resident
University of South Alabama Medical Center, Mobile, AL |
| 1989 - 1990 | Chief Medical Resident
University of South Alabama Medical Center
Mobile, AL |
| 1990 - 1991 | Clinical Pulmonary Fellow
Department of Medicine, University of California San Francisco
San Francisco, CA |
| 1991 - 1992 | Critical Care Fellow
Department of Anesthesia and Critical Care
University of California San Francisco, San Francisco, CA |
| 1992 - 1994 | Postdoctoral Research Fellow
Cardiovascular Research Institute
University of California San Francisco, San Francisco, CA |

4. Additional Leadership Training

- | | |
|-------------|---|
| 2005 – 2006 | Stanford Physician Leadership Development Program
Stanford Hospital and Clinics |
| 2007 | Leadership Development for Physicians in Academic Health Centers
Harvard School of Public Health
Center for Continuing Professional Education, Boston, MA |

- 2011 Forces of Change: New Strategies for the Evolving Health Care Marketplace
Executive Education Program
Harvard School of Public Health
Center for Continuing Professional Education, Boston, MA
- 2014 Clinical Effectiveness Leadership Training (CELT)
Stanford Health Care
- 2016 Women Executives in Health Care: Positioning for the Future
Harvard School of Public Health
Center for Executive and Continuing Professional Education, Boston, MA

5. Board Eligibility, Certification and Licensure

- 1989 -- present American Board of Internal Medicine certified, Internal Medicine
- 1990 -- present Medical Licensure, Medical Board of California
- 1992 -- 2023 ABIM Certified, Pulmonary Medicine
- 1993 -- present ABIM Certified, Critical Care Medicine

C. Complete Employment Record

- Assistant Professor of Medicine 09/94 -12/98
Division of Pulmonary and Critical Care Medicine
Director of Pulmonary HIV Outpatient Clinic
Louisiana State University Medical Center, New Orleans, LA
- Acting Assistant Professor of Medicine 01/99 - 05/99
Division of Pulmonary and Critical Care Medicine
Stanford University Medical Center, Stanford, CA
- Assistant Professor of Medicine 06/99-10/06
Division of Pulmonary and Critical Care Medicine
Stanford University, Stanford, CA
- Associate Professor of Medicine 11/06-12/11
Division of Pulmonary and Critical Care Medicine
Stanford University, Stanford, CA
- Professor of Medicine, continuing term 01/12-present
Division of Pulmonary and Critical Care Medicine
Stanford University, Stanford, CA
- Vice Chair, Clinical Affairs 05/07 – 08/08
Department of Medicine
Stanford University, Stanford, CA
- Vice Chair, Quality – Implementation 01/15 – 01/17
Department of Medicine
Stanford University, Stanford, CA
- Associate Chief Medical Officer, Patient Care Services 06/15 – 09/23

(changed to Inpatient Care Services 1/21)
Stanford Health Care, Stanford, CA

Senior Vice Chair for Clinical Affairs 12/16 – present
Department of Medicine
Stanford University, Stanford, CA

Interim Chief Quality Officer 03/17 – 07/18
Stanford Health Care, Stanford, CA

Chief Physician Executive 01/19 – present
Stanford Medicine Risk Authority
Stanford Health Care, Stanford, CA

D. Public and Professional Service

1. Activities: Stanford University Medical Center

Associate Director of the Intensive Care Unit	1999 – 2020
Director of the Intensive Care Units	2021 – 2023
Associate Director of the Heart-Lung and Lung Transplant Program	1999 – 2004
Fellowship Director, Pulmonary and Critical Care Medicine	2001 – 2002
Medical School Admissions Panel	2002 – 2004
Clinic Chief, Chest Clinic	2002 – 2004
Clinical Operations Committee	2002 – 2004
Internal Medicine Residency Review Committee	2002 – 2004
SHC Ethics Committee	2002 – 2004
Committee on Residency Training and Clinical Service	2003 – 2004
Continuing Quality Improvement in the ICU Committee	2003 – present
Medical School Faculty Senate, Senator-at-Large clinical alternate	2003 – 2004
Interim Director, Heart-Lung and Lung Transplant Program	2005
Chair, SHC Rapid Response Team Committee	2005 – 2007
Chair, SHC Medical Emergency Response Team Committee	2007 – 2011
SHC Quality Improvement and Patient Safety Committee	2007 – 2008
Dean’s Task Force for Clinical Excellence	2007 – 2008
Senior Physicians (Disaster) Management Committee	2008 – 2020
SHC Quality, Patient Safety, and Effectiveness Committee	2009 – present
SHC Service Medical Director	2009 – 2021
Patient Safety Committee Co-Chair (previously Quality Steering Cmttee)	2010 – 2021
Credentials Committee (Chair 2010 – 2012)	2010 – present
Care Improvement Committee	2010 – present
Care Improvement Committee, Chair	2013 – 2018
New Hospital Build Steering Committee	2011 – 2014
Clinical Space and Transition Cabinet	2011 – 2020
Vice Chief of Staff, SHC	2010 – 2011
Chief of Staff, SHC	2011 – 2014
SHC Board of Directors	2011 – 2014
Immediate Past Chief of Staff, SHC	2014 -- 2020
Cardiothoracic Surgery Chair Search Committee	2012 – 2013
Stanford University Malpractice Indemnity & Trust Board of Directors	2013 – 2024
500P (New Hospital) Activation Committee Co-Chair	2015 -- 2019
Stanford Medicine Safety, Quality, and Value Committee	2015 -- present
Fellowship Director, Critical Care Medicine	2015 – 2018
Emergency Medicine Department Task Force	2015

Emergency Medicine Chair Search Committee	2016 – 2018
General Surgery Division Chief Search Committee	2016
Hospitalist Medicine Division Chief Search Committee	2016
Concurrent Surgery Task Force	2016
Institutional Review Board	2016
500P MD Advisory Council Co-Chair	2018 – 2020
Work Place Violence Executive Committee Co-Chair	2019 – 2023
Anesthesia Chair Search Committee	2020 – 2021
300P Space Cabinet	
Physician Workspace and Respite Space Committee Co-Chair	
Acute Care Surgery Section Chief Search Committee	2022 - 2023
Stanford Medicine Ethics Director Search Committee	2023

2. National Activities

American Thoracic Society (ATS) Health Care Policy Committee	1999 - 2001
ATS Health Care Policy Committee Chairperson	2000 - 2001
ATS Government Relations Committee	2000 - 2002
ATS Website Editorial Board	2000 - 2002
American College of Chest Physicians Credentials Committee	2000 - 2004
Ad hoc Reviewer, The American Journal of Medicine	2000 - present
Ad hoc Reviewer, Chest	2000 - present
Ad hoc Reviewer, Critical Care Medicine	2000 - present
Ad hoc Reviewer, American Journal of Respiratory and Critical Care Medicine	2003 - present
ATS Training Committee	2003 - 2007
Advanced Trauma Life Support instructor	2003 - 2008
ATS Critical Care Assembly Planning Committee	2012 - 2013

3. Academic Seminars: Stanford University

“To Transfuse or Not to Transfuse? Evidence-Based Medicine in the ICU” Department of Medicine Grand Rounds, Stanford University	1999
“Novel Therapies for Sepsis: What Have We Learned?” UCSF Stanford International Medical Services Telemedicine Education Project in Asia, Stanford University	1999
“Chronic Lung Disease and End-of-Life Decisions” Nursing Education Day Hoover Pavilion, Stanford University	1999
“Acute Respiratory Distress Syndrome” “Anemia in the ICU” “Sedation, analgesia, and neuromuscular blockade” “Mechanical ventilation” “Pulmonary embolism” ICU Lecture Series, Stanford University	1999 – present
“Venous Thromboembolism”	1999 – present
Critical Care Nurses Continuing Education Series Hoover Pavilion, Stanford University	
“Acid Base Disturbances and Interpretation of Arterial Blood Gases”	2001 – 2002

Surgical Housestaff Core Lecture Series, Stanford University,	
“The Acute Respiratory Distress Syndrome – Pathophysiology and Management Strategies” Stanford International Medical Services Telemedicine Education Project in Asia, Stanford University	2001
“Acute Respiratory Distress Syndrome – Pathophysiology and Management Strategies” Surgical Housestaff Core Lecture Series, Stanford University	2002
“Sepsis, inflammation, and coagulation: Current concepts.” Department of Medicine Grand Rounds, Stanford University	2002
"Lung transplantation: Current challenges and controversies." Department of Medicine Grand Rounds, Stanford University	2005
“Clots in bad spots: What we know about pulmonary embolism and what we don’t” Department of Medicine Grand Rounds, Stanford University	2007
“Surviving and Thriving in a Tough Environment: Unconscious Bias and Microbehaviors” MS in PA Studies Program, Stanford University School of Medicine	2019

E. Post-degree Honors and Awards

1. Memberships in Professional Organizations

American Thoracic Society	1990 - present
Member, Health Care Policy Committee	1999 - 2001
Chair, Health Care Policy Committee	2000 - 2001
Member, Government Relations Committee	2000 - 2002
Member, Website Editorial Board	2000 - 2002
Member, Training Committee	2004 – 2007
American College of Chest Physicians	1990 - 2017
Fellow, American College of Chest Physicians	1998 - 2017
Member, Credentials Committee	2000 - 2004
Society of Critical Care Medicine	1999 – 2024

2. Honors and Awards

Leadership Development in Pulmonary and Critical Care Medicine, American College of Chest Physicians	1999
Chief Medical Residents’ Teaching Award, Stanford University	2003
Excellence in Teaching, Stanford University School of Medicine	2004
Pulmonary and Critical Care Teaching Award, Stanford University	2004
Stanford Physician Leadership Development Program	2005 – 2006
Alpha Omega Alpha, University of South Alabama	2006
Stanford School of Medicine Faculty Fellows Program	2007

Denise O’Leary Award for Clinical Excellence 2008
ABIM Foundation’s John A. Benson Jr., MD
Professionalism Article Prize 2018

3. Other Study and Research Opportunities

- 1) SmithKline Beecham 1999 - 2000
“Randomized, 24 week, double-blind, placebo-controlled, parallel group study to evaluate the efficacy, safety and tolerability of Ariflo TM (15 mgBID) in patients with chronic obstructive pulmonary disease COPD.” Co-PI.
- 2) Astra Zeneca 6/16/00 -12/30/00
“A 3-month, multi-centre, multinational, double-blind, group comparative study to investigate the effects of AR-C68397 AA via pMDI compared with placebo in adult patients with (COPD).” PI
- 3) Jason Christie, MD, University of Pennsylvania (Lilly) 3/21/03 – 2/14/07
“A Multicenter Prospective Cohort Study Examining the Role of Protein C (activated) in Early ARDS.” Stanford site PI
- 4) Unfunded 2002 – 2005
“Investigation of the training and use of point-of-care ultrasound by intensive care specialists” Co-PI with David Liang, MD
- 5) Unfunded 2002 - 2005
“Upper Extremity Deep Venous Thrombosis in Critically Ill Patients: Risk Factors, Outcomes, and the Effects of Prophylaxis.” PI
- 6) Ono Pharma USA 12/10/03-4/30/04
“A four week, double blind, placebo-controlled exploratory evaluation of FEV1.0 changes and safety of ONO-6126 in patients with chronic obstructive pulmonary disease (COPD).” PI
- 7) NHLBI P50 HL74005-SCOOR 5/1/05 – 2007
"Prospective, Randomized Clinical Trial of Activated Protein C (Xigris) versus Placebo for the Treatment of Acute Lung Injury" Stanford site Co-PI with Rochelle Dicker.
PI: Michael Matthay, MD
- 8) NIH 5-R01-HL-081619-02 2/15/07-1/31/12
“Genetics of Primary Graft Dysfunction” Stanford site PI.
PI: Jason Christie, MD
- 9) NIH R01-HL087115 8/15/07 – 5/31/20
“Clinical Risk Factors for Primary Graft Dysfunction” Stanford site PI
This is a multicentered cohort study investigating clinical variables as risk factors for acute lung injury (primary graft dysfunction) following lung transplantation. Stanford site PI.
PI: Jason Christie, MD

III. BIBLIOGRAPHICAL INFORMATION

Peer-Review Journal Articles

1. Yung RC, **Weinacker AB**, Steiger DJ, Miller TR, Stern EJ, Salmon CJ, Luistro MG, Kuntz S, Golden JA. Upper and middle lobe bronchoalveolar lavage to diagnose *Pneumocystis carinii* pneumonia. Am Rev Respir Dis 1993; 148:1563-1566.
2. Stern EJ, Webb WR, **Weinacker A**, Muller NL. Idiopathic giant bullous emphysema (vanishing lung syndrome): imaging findings in nine patients. Am J Roentgenol 1994; 162:279-282.
3. **Weinacker A**, Chen A, Agrez M, Cone R, Nishimura S, Wayner E, Pytela R, Sheppard D. Role of the integrin $\alpha v \beta 6$ in cell attachment to fibronectin: Heterologous expression of intact and secreted forms of the receptor. J Biol Chem 1994; 269:6940-6948.
4. Cone RI, **Weinacker A**, Chen A, Sheppard D. Effects of β subunit cytoplasmic domain deletions on the recruitment of the integrin $\alpha v \beta 6$ to focal contacts. Cell Adhesion Comm 1994; 2:101-113.
5. **Weinacker A**, Ferrando R, Elliott M, Hogg J, Balmes J, Sheppard D. Distribution of integrins $\alpha v \beta 6$ and $\alpha 9 \beta 1$ and their known ligands, fibronectin and tenascin, in human airways. Am J Respir Cell Mol Biol 1995; 5:547-556.
6. Schwarzenberger P, Lei D, Freeman SM, Ye P, **Weinacker A**, Theodossious C, Summer W, Kolls JK. Antitumor activity with a HSV-tk gene modified cell line PA-1-STK in malignant mesothelioma. Am J Respir Cell Mol Biol 1998; 19:333-337.
7. Schwarzenberger P, Harrison L, **Weinacker A**, Marrogi A, Byrne P, Ramesh R, Theodossiou C, Gaumer R, Summer W, Freeman SM, Kolls JK. The treatment of malignant mesothelioma with a gene modified cancer cell line: a phase I study. Hum Gene Ther 1998; 9:2641-9.
8. Schwarzenberger P, Harrison L, **Weinacker A**, Gaumer R, Theodossiou C, Summer W, Ye P, Marrogi AJ, Ramesh R, Freeman S, Kolls J. Gene therapy for malignant mesothelioma: a novel approach for an incurable cancer with increased incidence in Louisiana. J La State Med Soc 1998 Apr; 150(4):168-74. PMID: 9610071.
9. Tafreshi MJ, **Weinacker AB**. Beta-adrenergic-blocking agents in bronchospastic diseases: a therapeutic dilemma. Pharmacotherapy 1999; 19(8):974-978.
10. Shafazand S, Doyle R, Ruoss S, **Weinacker A**, Raffin TA. Inhalational anthrax: Epidemiology, diagnosis, and management. Chest 1999; 116:1369-1376.
11. **Weinacker AB**, Vaszar L. Acute respiratory distress syndrome: Physiology and new management strategies. Annu Rev Med 2001; 52:221-37.
12. Singer LG, **Weinacker AB**, Levin L, Doyle RL, Theodore J. Diagnostic yield of screening colonoscopies in lung transplant candidates. Transplantation 2001; 72:530-532.
13. Leonard CT, **Weinacker A**, Berry G, Whyte RI. A cystic upper lobe lesion in a healthy non-smoking male. Chest 2001; 120:1725-1727.
14. Angelotti T, Krishna G, Scott J, **Weinacker AB**. Nodular invasive tracheobronchitis due to *Aspergillus* in a patient with systemic lupus erythematosus. Lupus 2002; 11:325-328.
15. Vaszar LT, **Weinacker AB**, Henig NR, Raffin TA. Ethical issues in the long-term management of progressive neuromuscular diseases. Seminars in Respiratory and Critical Care Medicine 2002; 23:307-314.
16. Shafazand S, **Weinacker A**. Blood cultures in the critical care unit: Improving utilization and yield. Chest 2002; 122:1727-1736.
17. Fowler RA, Flavin KE, Barr J, **Weinacker AB**, Gould MK. Variability in prescribing patterns and outcomes in patients with clinically suspected ventilator-associated pneumonia. Chest 2003; 123:835-844.
18. Takaoka ST, **Weinacker AB**. The value of preoperative pulmonary rehabilitation. Thorac Surg Clin 2005; 15: 203-11.
19. Moffatt SD, Demers P, Robbins RC, Doyle R, **Weinacker A**, Henig N, Theodore J, Reitz

- BA, Whyte RI. Lung transplantation: A decade of experience. J Heart Lung Transplant 2005;24:145-151.
20. Omidvari K, Lessnau K, Kim J, Mercante D, **Weinacker A**, Mason C. Smoking in contemporary American cinema. Chest 2005; 128:746-754.
 21. Lin P, Martin B, **Weinacker A**, So Y. High dose cyclophosphamide efficacy in a patient with refractory anti-MuSK positive myasthenia gravis. Muscle & Nerve 2006; 33:433-435.
 22. Christie, JD, Robinson N, Ware LB, Plotnick M, De Andrade J, Lama V, Milstone A, Orens J, **Weinacker A**, Demissie E, Bellamy S, Kawut SM. Association of Protein C & Type-1 Plasminogen Activator Inhibitor with Pulmonary Graft Dysfunction. Am J Respir Crit Care Med 2007;175:69-74.
 23. Zamanian R, Haddad F, Doyle RL, **Weinacker AB**. Management strategies for patients with pulmonary hypertension in the intensive care unit. Crit Care Med 2007;35:2037-2050.
 24. Covarrubias M, Ware LB, Kawut SM, De Andrade J, Milstone A, **Weinacker A**, Orens J, Lama V, Wille K, Bellamy S, Shah C, Demissie E, Christie JD for the Lung Transplant Outcomes Group. Plasma Intercellular Adhesion Molecule-1 and von Willebrand Factor in Primary Graft Dysfunction After Lung Transplantation. Am J Transplant 2007;7:2573-2578.
 25. Liu KD, Levitt J, Zhuo H, Kallet RH, Brady S, Steingrub J, Siege M, Soto G, Peterson M, Chesnutt M, **Weinacker A**, Thompson BT, Eisner MD, and Matthay MA. Randomized Clinical Trial of Activated Protein C for the Treatment of Acute Lung Injury. Am J Crit Care Med. 2008;1786:618-23.
 26. Hoffman SA, Wang L, Shah CV, Ahya VN, Pochettino A, Olthoff K, Shaked A, Wille K, Lama VN, Milstone A, Ware LB, Orens J, **Weinacker A**, Demissie E, Bellamy S, Kawut SM, Hancock WW, Christie JD; Lung Transplant Outcomes Group. Plasma cytokines and chemokines in primary graft dysfunction post-lung transplantation. Am J Transplant. 2009;9:389-96. Epub 2008 Dec 15.
 27. Kawut SM, Okun J, Shimbo D, Lederer DJ, DeAndrade J, Lama V, Milstone A, Ware LB, **Weinacker A**, Demissie E, Christie JD. Soluble P-selectin and the risk of primary graft dysfunction after lung transplantation. Chest 2009;136:237-44.
 28. Christie JD, Shah CV, Kawut SM, Mangalmurti N, Lederer DJ, Sonett JR, Ahya VN, Palmer SM, Wille K, Lama V, Shah PD, Shah A, **Weinacker A**, Deutschman CS, Kohl BA, Demissie E, Bellamy S, Ware LB, for the Lung Transplant Outcomes Group : Plasma Levels of Receptor for Advanced Glycation End-Products (sRAGE), Blood Transfusion, and Risk Of Primary Graft Dysfunction. Am J Respir Crit Care Med 2009;180:1010-15.
 29. Christie JD, Bellamy S, Ware LB, Lederer D, Hadjiliadis D, Lee J, Robinson N, Localio AR, Wille K, Lama V, Palmer S, Orens J, **Weinacker A**, Crespo M, Demissie E, Kimmel SE, Kawut SM. Construct validity of the definition of primary graft dysfunction after lung transplantation. J Heart Lung Transplant 2010;29:1231-9. [Epub 2010 July 22]
 30. Fang A, Studer S, Kawut SM, Ahya VN, Lee J, Wille K, Lama V, Ware LB, Orens J, **Weinacker A**, Palmer SM, Crespo M, Lederer DJ, Deutschman CS, Kohl BA, Bellamy, S, Demissie E, Christie JD: Elevated Pulmonary Artery Pressure is a Risk Factor for Primary Graft Dysfunction Following Lung Transplantation for Idiopathic Pulmonary Fibrosis. Chest 2011;139:752-787. [Epub 2010 Sept 23]
 31. Diamond JM, Kawut SM, Lederer DJ, Ahya VN, Kohl B, Sonett J, Palmer SM, Crespo M, Wille KM, Lama V, Shah PD, Orens J, Bhorade S, **Weinacker A**, Demissie E, Bellamy S, Christie JD, and Ware LB for the Lung Transplant Outcomes Group. Elevated Plasma Clara Cell Secretory Protein Concentration is Associated with High Grade Primary Graft Dysfunction. Am J Transplant 2011;11:561-567. [Epub 2011 Feb 27]

32. Sims M, Beers M, Ahya V, Kawut S, Sims K, Lederer D, Palmer S, Wille K, Lama V, Shah P, Orens J, Borhade S, Crespo MM, **Weinacker A**, Demissie E, Bellamy S, Christie J, Ware L. Effect of Single versus Bilateral Lung Transplantation on Plasma Surfactant Protein D Levels in Idiopathic Pulmonary Fibrosis. Chest 2011 Aug;140(2):489-96, Epub ahead of print.
33. Lederer DJ, Kawut SM, Wickersham N, Winterbottom C, Borhade S, Palmer SM, Lee J, Diamond JM, Wille KM, **Weinacker A**, Lama VN, Crespo M, Orens JB, Sonett JR, Arcasoy SM, Ware LB, Christie JD; for the Lung Transplant Outcomes Group. Obesity and Primary Graft Dysfunction after Lung Transplantation: The LTOG Obesity Study. Am J Respir Crit Care Med 2011 Nov 1;184(9):1055-61. [Epub ahead of print]
34. Diamond JM, Lederer DJ, Kawut SM, Lee J, Ahya VN, Bellamy S, Palmer SM, Lama VN, Borhade S, Crespo M, Demissie E, Sonett J, Wille K, Orens J, Shah PD, **Weinacker A**, Weill D, Kohl BA, Deutschman CC, Arcasoy S, Shah AS, Belperio JA, Wilkes D, Reynolds JM, Ware LB, Christie JD; for the Lung Transplant Outcomes Group. Elevated Plasma Long Pentraxin-3 Levels and Primary Graft Dysfunction After Lung Transplantation for Idiopathic Pulmonary Fibrosis. Am J Transplant. 2011 Nov;11(11):2517-22. doi: 10.1111/j.1600-6143.2011.03702.x. Epub 2011 Aug 22. PMID: 21883907
35. Pickham D, Helfenbein E, Shinn JA, Chan G, Funk M, **Weinacker A**, Liu JN, Drew BJ. High prevalence of corrected QT interval prolongation in acutely ill patients is associated with mortality: Results of the QT in Practice (QTIP) Study. Crit Care Med. 2012 Feb;40(2):394-9. doi: 10.1097/CCM.0b013e318232db4a. PMID 22001585.
35. Diamond JM, Meyer NJ, Feng R, Rushefski M, Lederer DJ, Kawut SM, Lee JC, Cantu E, Shah RJ, Lama VN, Borhade S, Crespo M, Demissie E, Sonett J, Wille K, Orens J, **Weinacker A**, Weill D, Arcasoy S, Shah PD, Belperio JA, Wilkes D, Ware LB, Palmer SM, Christie JD; for the Lung Transplant Outcomes Group. Variation in PTX3 Is Associated with Primary Graft Dysfunction after Lung Transplantation. Am J Respir Crit Care Med. 2012 Sep 15;186(6):546-552. Epub 2012 Jul 19.
36. Shah RJ, Bellamy SL, Localio AR, Wickersham N, Diamond JM, **Weinacker A**, Lama VN, Borhade S, Belperio JA, Crespo M, Demissie E, Kawut SM, Wille KM, Lederer DJ, Lee JC, Palmer SM, Orens J, Reynolds J, Shah A, Wilkes DS, Ware LB, Christie JD. A panel of lung injury biomarkers enhances the definition of primary graft dysfunction (PGD) after lung transplantation. J Heart Lung Transplant. 2012 Sep;31(9):942-9. Epub 2012 Jun 12.
37. Diamond JM, Porteous MK, Cantu E, Meyer NJ, Shah RJ, Lederer DJ, Kawut SM, Lee J, Bellamy SL, Palmer SM, Lama VN, Borhade SM, Crespo M, Demissie E, Wille K, Orens J, Shah PD, **Weinacker A**, Weill D, Arcasoy S, Wilkes DS, Ware LB, Christie JD. Elevated plasma angiopoietin-2 levels and primary graft dysfunction after lung transplantation. PLoS One. 2012; 7 (12): e51932.
38. Diamond JM, Lee JC, Kawut SM, Shah RJ, Localio AR, Bellamy S, Lederer DJ, Cantu E, Kohl BA, Lama VN, Borhade S, Crespo M, Demissie E, Sonnett J, Wille K, Orens J, Shah AS, **Weinacker A**, Arcasoy S, Shah PD, Wilkes DS, Ware LB, Palmer SM, Christie JD. Clinical Risk Factors for Primary Graft Dysfunction after Lung Transplantation. Am J Respir Crit Care Med 2013; 187:527-84.
39. Shah RJ, Diamond JM, Cantu E, Lee JC, Lederer DJ, Lama VN, Orens J, **Weinacker A**, Wilkes DS, Borhade S, Wille KM, Ware LB, Palmer SM, Crespo M, Localio AR, Demissie EJ, Kawut SM, Bellamy SL, Christie JD. Latent class analysis identifies distinct phenotypes

of primary graft dysfunction after lung transplantation. *Chest* 2013; 144:616-22. [Epub ahead of print]

40. Shah RJ, Wickersham N, Lederer DJ, Palmer SM, Cantu E, Diamond JM, Kawut SM, Lama VN, Borhade S, Crespo M, Demissie E, Sonett J, Wille K, Orens J, **Weinacker A**, Shah P, Arcasoy S, Wilkes DS, Christie JD*, Ware LB* Pre-operative plasma club (clara) cell secretory protein levels are associated with primary graft dysfunction after lung transplantation. *Am J Transplant* 2014 Feb;14(2):446-52.
41. Shah RJ, Emtiazjoo AM, Diamond JM, Smith PA, Roe DW, Wille KM, Orens JB, Ware LB, **Weinacker A**, Lama VN, Borhade SM, Palmer SM, Crespo M, Lederer DJ, Cantu E, Eckert GJ, Christie JD, Wilkes DS. Plasma complement levels are associated with primary graft dysfunction and mortality after lung transplantation. *Am J Respir Crit Care Med* 2014 Jun 15;189(12):1564-7.
42. Diamond JM, Akimova T, Kazi A, Shah RJ, Cantu E, Feng R, Levine MH, Kawut SM, Meyer NJ, Lee JC, Hancock WW, Aplenc R, Ware LB, Palmer SM, Borhade S, Lama VN, **Weinacker A**, Orens J, Wille K, Crespo M, Lederer DJ, Arcasoy S, Demissie E, Christie JD; Lung Transplant Outcomes Group. Genetic variation in the prostaglandin E2 pathway is associated with primary graft dysfunction. *Am J Respir Crit Care Med* 2014 Mar 1;189(5):567-75.
43. Shah RJ, Diamond JM, Cantu E, Flesch J, Lee JC, Lederer DJ, Lama VN, Orens J, **Weinacker A**, Wilkes DS, Roe D, Borhade S, Wille KM, Ware LB, Palmer SM, Crespo M, Demissie E, Sonnet J, Shah A, Kawut SM, Bellamy SL, Localio AR, Christie JD. Objective Estimates Improve Risk Stratification for Primary Graft Dysfunction after Lung Transplantation. *Am J Transplant* 2015 Aug;15(8):2188-96. Epub 2015 Apr 15. PMID: 25877792
44. Cantu E, Suzuki Y, Diamond JM, Ellis J, Tiwari J, Beduhn B, Nellen JR, Shah R, Meyer NJ, Lederer DJ, Kawut SM, Palmer SM, Snyder LD, Hartwig MG, Lama VN, Borhade S, Crespo M, Demissie E, Wille K, Orens J, Shah PD, **Weinacker A**, Weill D, Wilkes D, Roe D, Ware LB, Wang F, Feng R, Christie JD; Lung Transplant Outcomes Group. Protein Quantitative Trait Loci Analysis Identifies Genetic Variation in the Innate Immune Regulator TOLLIP in Post-Lung Transplant Primary Graft Dysfunction Risk. *Am J Transplant*. 2016 Mar;16(3):833-40. PMID: 26663441
45. Diamond JM, Porteous MK, Jackson Roberts L 2nd, Wickersham N, Rushefski M, Kawut SM, Shah RJ, Cantu E 3rd, Lederer DJ, Chatterjee S, Lama VN, Borhade S, Crespo M, McDyer J, Wille K, Orens J, **Weinacker A**, Arcasoy S, Shah PD, Wilkes DS, Hage C, Palmer SM, Snyder L, Calfee CS, Ware LB, Christie JD; Lung Transplant Outcomes Group.. The relationship between plasma lipid peroxidation products and primary graft dysfunction after lung transplantation is modified by donor smoking and reperfusion hyperoxia. *J Heart Lung Transplant*. 2016 Apr;35(4):500-7. PMID: 26856667
46. Kane M, **Weinacker A**, Arthofer R, Seay-Morrison T, Elfman W, Ramirez M, Ahuja N, Pickham D, Hereford J, Welton M. A Multidisciplinary Initiative to Increase Inpatient Discharges Before Noon. *J Nurs Adm*. 2016 Dec;46(12):630-635. PMID: 27851703
47. Porteous MK, Lee JC, Lederer DJ, Palmer SM, Cantu E, Shah RJ, Bellamy SL, Lama VN, Borhade SM, Crespo MM, McDyer JF, Wille KM, Localio AR, Orens JB, Shah PD, **Weinacker AB**, Arcasoy S, Wilkes DS, Ware LB, Christie JD, Kawut SM, Diamond JM; Lung Transplant Outcomes Group. Clinical Risk Factors and Prognostic Model for Primary Graft Dysfunction after Lung Transplantation in Patients with Pulmonary Hypertension.

- Ann Am Thorac Soc. 2017 Oct;14(10):1514-22. Originally published in Press as doi: 10.1513/AnnalsATS.201610-810OC. [Epub ahead of print] PMID: 28719755 on July 18.
48. Cantu E, Diamond JM, Suzuki Y, Lasky J, Schaufler C, Lim B, Shah R, Porteous M, Lederer DJ, Kawut SM, Palmer SM, Snyder LD, Hartwig MG, Lama VN, Bhorade S, Bermudez C, Crespo M, McDyer J, Wille K, Orens J, Shah PD, **Weinacker A**, Weill D, Wilkes D, Roe D, Hage C, Ware LB, Bellamy SL, Christie JD, the Lung Transplant Outcomes Group. Quantitative Evidence for Revising the Definition of Primary Graft Dysfunction After Lung Transplant. Am J Respir Crit Care Med. 2018 Jan;197(2):235-43. Originally published in Press as doi 10.1164/rccm.201706-1140OC. [Epub ahead of print] PMID:28872353 on Sep 5, 2017.
 49. Shaver CM, Wickersham N, McNeil JB, Nagata H, Adam Miller A, Landstreet SR, Kuck JL, Diamond JM, Lederer DJ, Kawut SM, Palmer SM, Wille KM, **Weinacker A**, Lama VN, Crespo M, Orens JB, Shah PD, Hage CA, Cantu III E, Porteous MK, Dhillon G, McDyer J, Bastarache JA, Christie JD, Ware LB, and the Lung Transplant Outcomes Group. Cell-free hemoglobin promotes primary graft dysfunction through oxidative lung endothelial injury. JCI Insight. 2018 Jan 25;3(2):e98546. doi:10.1172/jci.insight.98546
 50. Hopkins J, Hedlin H, **Weinacker A**, Desai M. Patterns of Disrespectful Physician Behavior at an Academic Medical Center: Implications for Training, Prevention, and Remediation. Acad Med. 2018 Nov;93(11):1679-1685. doi: 10.1097/ACM.0000000000002126. [Epub ahead of print] PMID:29319539
 51. Kane M, Rohatgi N, Heidenreich P, Thakur A, Winget M, Shum K, Hereford J, Shieh L, Lew T, Horn J, Chi J, **Weinacker A**, Seay-Morrison T, Ahuja N. Lean-Based Redesign of Multidisciplinary Rounds on General Medicine Service. J Hosp Med 2018 Jul 1;13(7):482-485. doi: 10.12788/jhm.2908. [Epub ahead of print] PMID: 29394300
 52. Martin JA, Porteous MK, Cantu E, Lederer DJ, Snyder L, **Weinacker A**, Orens JB, Shah PD, Lama VN, McDyer J, Wille KM, Hage CA, Singer J, Ware LB, Oyster M, Brown M, Christie JD, Diamond J. Risk Factors for Primary Graft Dysfunction in Patients with Cystic Fibrosis Receiving Lung Transplants. J Heart Lung Transplant M.ELSEVIER SCIENCE INC. 2019: S147. <https://doi.org/10.1016/j.healun.2019.01.352>
 53. Natalini JG, Diamond JM, Porteous MK, Lederer DJ, Wille KM, **Weinacker AW**, Orens JB, Shah PD, Lama VN, McDyer JF, Snyder LD, Hage CA, Singer JP, Ware LB, Cantu E, Oyster M, Kalman L, Christie JD, Kawut SM, Bernstein EJ. Risk of Primary Graft Dysfunction Following Lung Transplantation in Selected Adults with Connective Tissue Disease-associated Interstitial Lung Disease. J Heart Lung Transplant 2021 May;40(5):351-358. doi: 10.1016/j.healun.2021.01.1391. Epub 2021 Jan 23. PMID: 33637413
 54. Diamond JM, Cantu E, Oyster M, Hsu J, Localio R, Shashaty M, Koons B, Crespo M, Kalman L, Calfee C, Singer J, Greenland J, Kukreja J, Snyder L, Hartwig M, McDyer J, Shah P, Orens J, Wille K, Hage C, **Weinacker A**, Benvenuto L, Lama V, Christie J. Predicting PGD after Lung Transplantation. ELSEVIER SCIENCE INC. 2021: S156
 55. Cantu E, Diamond JM, Cevasco M, Suzuki,Y, Crespo M, Clausen E, Dallara L, Ramon CV, Harmon MT, Bermudez C, Benvenuto L, Anderson M, Wille KM, **Weinacker A**, Dhillon GS, Orens J, Shah P, Merlo C, Lama V, McDyer J, Snyder L, Palmer S, Hartwig M, Hage CA, Singer J, Calfee C, Kukreja J, Greenland JR, Ware LB, Localio R, Hsu J, Gallop R, Christie JD. Contemporary trends in PGD incidence, outcomes, and therapies. J Heart Lung Transplant Epub 2022 August. <https://doi.org/10.1016/j.healun.2022.08.013>. PMID: 36216694

56. Diamond JM, Cantu E, Calfee CS, Anderson MR, Clausen ES, Shashaty MGS, Courtwright AM, Kalman L, Oyster M, Crespo MM, Bermudez CA, Benvenuto L, Palmer SM, Snyder LD, Hartwig MG, Todd JL, Wille K, Hage C, McDyer JF, Merlo CA, Shah PD, Orens J, Dhillon GS, **Weinacker AB**, Lama VN, Patel MG, Singer JP, Hsu J, Localio AR, Christie JD. The impact of donor smoking on primary graft dysfunction and mortality after lung transplantation. *Am J Respir Crit Care Med*, 2024 Jan 1;209(1):91-100. doi: 10.1164/rccm.202303-0358OC. PMID: 37734031

Non Peer-Reviewed Articles

1. Kolls JK, Nelson S, **Weinacker A**. Gene therapy for lung diseases. *Clin Pulm Med* 1995; 29(4):238-242.
2. **Weinacker A**. Sedatives, analgesics and neuromuscular blocking agents in critically ill patients. *Mediguide* 1996; 2(6):1-8.
3. Schwarzenberger P, Harrison L, **Weinacker A**, Theodossiou C, Gaumer R, Summer W, Freeman S, Ramesh R, Kolls J. Gene therapy for malignant mesothelioma: A novel approach for an incurable cancer with increased incidence in Louisiana. *J La State Med Soc* 1998; 150:168-174.
4. **Weinacker A**. Use of Analgesics, Sedatives and neuromuscular blocking agents in critically ill patients. *Clin Pulm Med* 1998; 1:50-59.
5. **Weinacker A**. Review questions in pulmonary and critical care medicine. *Resident & Staff Physician* 1998; 44(5):85-90.

Book Chapters

1. **Weinacker A** and Nelson S. *Prevention of pneumonia.* In: Parsons PE, and Heffner JE, eds. *Pulmonary and Respiratory Secrets.* Philadelphia: Hanley & Belfus, Inc., 1997, pp.171-178.
2. Reed K. and **Weinacker A**. *Non-cardiac chest pain.* In: Ali J, Summer WR, Levitzky MG, eds. *Pulmonary Pathophysiology: A Clinical Correlate.* New York: McGraw-Hill, Inc., 1999, pp. 65-88.
3. **Weinacker A**. *Pleural disease.* In: Ali J, Summer WR, Levitzky MG, eds. *Pulmonary Pathophysiology: A Clinical Correlate.* New York: McGraw-Hill, Inc., 1999, pp. 239-267.
4. Mason CM, **Weinacker AB**, Shellito JE. *Host defense networks in the lung: An Overview.* In: Niederman MS, Sarosi GA, Glassroth J, eds. *Respiratory Infections.* Philadelphia: Lippincott Williams & Wilkins, 2001, pp. 3-12.
5. McGee DC, **Weinacker AB**, Raffin TA. *Ethical concerns in managing critically ill patients.* In: Perillo JE and Dellinger RP, eds. *Critical Care Medicine: Principles of Diagnosis and Management in the Adult.* St. Louis: Mosby, 2001, pp. 1571-1585.

6. **Weinacker A** and Nelson S. *Prevention of pneumonia*. In: Parsons PE, and Heffner JE, eds. Pulmonary and Respiratory Secrets, 2/e. Philadelphia: Hanley & Belfus, Inc., 2001, pp. 188-197.
7. Singer LG, **Weinacker AB**, Theodore J. *Long term management and outcome of heart-lung and lung transplant recipients*. In: Baumgartner WA, Reitz B, Kasper E, Theodore J, eds. Heart and Lung Transplantation, 2/e. Philadelphia: W.B. Saunders Company, 2002, pp. 434-455.
8. Takaoka S, **Weinacker A**. *The value of preoperative pulmonary rehabilitation*. Thoracic Surgery Clinics 2005, 15(2):203-211.
9. Davis K, **Weinacker A**, Nelson S. *Prevention of pneumonia*. In: Parsons PE, and Heffner JE, eds. Pulmonary and Respiratory Secrets, 3/e. Philadelphia: Hanley & Belfus, Inc, 2006, pp. 226-231.

Editorials, Letters to the Editor

1. Gould M, Leonard C, **Weinacker A**, Raffin TA. Systematic reviews and evidence-based critical care medicine: a step in the right direction. Am J Med 1998, 105:551-553.
2. Faul JL, Doyle RL, **Weinacker AB**, Raffin TA. Quality of life and lung volume reduction surgery. Am J Crit Care 1999, 8:359-360.
3. McGee DC, **Weinacker AB**, Raffin TA. The patient's response to medical futility. Arch Int Med 2000; 160:1565-1566.
4. Shafazand S, Shigemitsu H, **Weinacker AB**. A brave new world: remote intensive care unit care for the 21st century. Crit Care Med 2000, 28:3945-3946.
5. McGee DC, **Weinacker AB**, Raffin TA. Withdrawing life support from the critically ill. Chest 2000, 118:1238-1239.
6. **Weinacker A**. Intensive care unit support of hematopoietic stem cell transplant recipients: A case for cautious optimism. Crit Care Med 2003, 31:1873-5.
7. **Weinacker A**. The “slow code” should be a “no code”. Am J Bioeth. 2011 Nov;11(11):27-9.
8. **Weinacker A**, Stapleton RD. Still a man’s world, but why? Crit Care. 2013;17:113.
9. Heidenreich P, Shieh L, Fassiotto M, Kahn J, **Weinacker A**, Smith R, Trockel MT, Shanafelt T, Palaniappan L. Letter to the Editor: Characteristics of Academic Physicians Associated With Patient Satisfaction. Am J Med Qual 2020 Jul/Aug;35(4):357-358. doi: 10.1177/1062860619876344. PMID 31529975. Epub 2019 Sep 17.

Invited Lectures

1. Analgesia, sedation, and neuromuscular blocking agents. Pulmonary/Critical Care Grand Rounds. The Mount Sinai Medical Center, New York, New York. October 9, 1996.

2. Lung volume reduction surgery. Chest 1997: 63rd Annual International Scientific Assembly. Slide session moderator. New Orleans, Louisiana. October 27, 1997.
3. HIV and the lung. Infectious Diseases Grand Rounds. University of South Alabama Medical Center, Mobile, Alabama. February 23, 1998.
4. Acute and chronic bronchitis: The role of antibiotics. Presented at the Update in Infectious Disease for the Primary Physician; Stanford University School of Medicine Division of Infectious Diseases and Geographic Medicine, Stanford, California. March 25, 2000.
5. Combining clinical research with a career as a clinician. American Thoracic Society International Conference Postgraduate Course, San Francisco, California. May 19, 2001.
6. Anemia in the critically ill: To transfuse or not to transfuse? American Thoracic Society International Conference Postgraduate Course, San Francisco, California. May 19, 2001.
7. Clots in bad spots: Pulmonary embolism 2001. University of South Alabama College of Medicine Alumni Association, Mobile, Alabama. June 23, 2001.
8. Anemia in the critically ill. American Society of Nephrology Meeting, San Francisco, California. October 12, 2001.
9. Anemia in the ICU. Medical Grand Rounds, Scripps Mercy Hospital, San Diego, California. (Visiting Professor) April 23, 2002.
10. Ethical Issues in the ICU. Medical Noon Conference, Scripps Mercy Hospital, San Diego, California. April 23, 2002.
11. Evidence-based guidelines for long-term ventilation. A National Symposium for Physicians, Nurses and Allied Health Professionals: Innovations in Pediatric and Adult Critical Care. Kohala Coast, Hawaii. September 27, 2002.
12. Interrelationship between inflammation, sepsis, and coagulation. A National Symposium for Physicians, Nurses and Allied Health Professionals: Innovations in Pediatric and Adult Critical Care. Kohala Coast, Hawaii. September 28, 2002.
13. Ethical decision-making in the ICU. Santa Barbara Cottage Hospital, Santa Barbara, CA. April 10, 2003.
14. Anemia in the critically ill: To transfuse or not to transfuse? Department of Medicine Grand Rounds. University of South Alabama Medical Center, Mobile, Alabama. (Visiting Professor) April 24, 2003.
15. Ethical decision-making in the ICU. Department of Medicine Noon Conference. University of South Alabama Medical Center, Mobile, Alabama. April 24, 2003.
16. Ethical issues in the ICU. Internal Medicine Noon Conference. Queen of Angels-Hollywood Presbyterian Medical Center, Los Angeles, California. June 20, 2003.
17. Treatment of anemia in the ICU. Intensive Care Nephrology Conference. Tulane University, New Orleans, LA. December 6, 2003.
18. Ventilator management: The basics. Stanford University Department of Anesthesia Residents' Annual Refresher Course. June 6, 2004.

19. Preventing Complications in the ICU. University of California, San Francisco Critical Care Update. June, 2005.
20. Controversies in the ICU: Which protocols are useful? California Thoracic Society Meeting, Carmel, CA. February 3, 2006
21. Acute Respiratory Distress Syndrome: An Update. St. Joseph's Medical Center, Stockton, CA. March 25, 2009.
22. Acute Respiratory Distress Syndrome: Challenges in the ICU in 2011. Teleconference lecture to Makati Medical Center, Makati City, Philippines. February 24, 2011.
23. Pulmonary embolism: What do we know about diagnosis and treatment? Medical Grand Rounds, Siriraj Mahildol University Hospital, Bangkok, Thailand. December 6, 2011.
24. Acute Respiratory Distress Syndrome: Pathophysiology and Management Strategies. Critical Care Noon Conference, Siriraj Mahildol University Hospital, Bangkok, Thailand, December 6, 2011.
25. Pulmonary embolism: What do we know about diagnosis and treatment? Medical Grand Rounds, Chang Gung Memorial Hospital, Taipei, Taiwan, December 8, 2011.
26. Acute Respiratory Distress Syndrome: Pathophysiology and Management Strategies. Critical Care Conference, Chang Gung Memorial Hospital, Taipei, Taiwan, December 9, 2011.
27. Update of inpatient management of polytrauma patients in the ICU. Opening ceremonies. Bangkok Hospital, Udon Thani, Thailand. December 12, 2012.
28. Late Career Practitioner Policy – the Good, the Bad, and the Unknown. Webinar sponsored by the National Association of Medical Staff Services and The American Health Lawyers Association. November 21, 2013.
29. Late Career Practitioner Policy: Appropriate and Defensible. Physician Insurers Association of America Medical Liability Conference, Washington, DC, May 12, 2016.
30. Late Career Practitioner Policy: Appropriate and Defensible. Webinar sponsored by Modern Healthcare. June 30, 2016.
31. Evolving Considerations for Late Career Practitioners. Medical Staff Update 2017: Issues and Strategies for California Hospital Medical Staffs. Seminar sponsored by Hooper, Lundy & Bookman, PC, Health Care Lawyers and Advisors. May 2, 2017.
32. Money talks: How Financial Incentives (and Disincentives) Impact QI. American Thoracic Society International Conference Postgraduate Course, Washington, D.C. May 20, 2017.
33. Stanford's Approach to Quality and Safety in Patient Care. Shao Yifu Hospital, HangZhou, China. September 26, 2018.
34. A History of Quality Improvement Efforts in the US and a Look to the Future. The First Affiliated Hospital of Nanchang University. Wuhan, China. September 27, 2018.
35. A History of Quality Improvement Efforts in the US and a Look to the Future. Xinxiang

Medical University No. 1 Affiliated Hospital. Xinxiang, China. September 28, 2018.

36. Stanford's Approach to Quality and Safety in Patient Care. People's Hospital of Lanling. Lanling, China. September 28, 2018.